Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Utvärdering av en intervention för att minska tiden till behandling för TAVI-patienter (TREAT)

3 november 2026 uppdaterad av: University Hospital, Rouen

Evaluation d'Une Intervention Pour Reduire le Delai de Traitement Des Patients Traites Par TAVI

Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).

Once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (AVR or TAVI) must be performed rapidly given the poor prognosis of the disease without treatment. Studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. This delay could also reduce the effectiveness of TAVI, thus affecting the performance of the healthcare system.

In this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for TAVI implanting centres) has been designed. The aim of this study is to evaluate the effectiveness of this intervention.

Studieöversikt

Status

Avslutad

Betingelser

Studietyp

Interventionell

Inskrivning (Faktisk)

828

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Brest, Frankrike
        • Brest University Hospital
      • Rouen, Frankrike
        • CHU de Rouen

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patient over 18 years of age;
  • Aortic stenosis
  • Indication of TAVI
  • Patient affiliated or benefiting from a health insurance scheme
  • Patient having read and understood the information letter and having signed the consent form

Exclusion Criteria:

  • TAVI indication not retained
  • Patient who are not fluent in French and have no one around them to translate,
  • Patient who do not have access to the Internet (at home or in their immediate environment)
  • Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ;
  • Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators
  • History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Inget ingripande: Control group

The randomized centres in this group will not change their practices.

Experimentell: Patient component

The randomized centres in this group will be required to present patients with:

  • A short introductory video, viewed on a tablet during hospitalization for coronary angiography,
  • A paper booklet,
  • A website.

Video, booklet, website

Experimentell: Organisational component

The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times.

Coronarography, CT-scan, anesthesia...

Experimentell: Patient and organisational components

The randomized centres in this group will have to implement the two components.

Video, booklet, website

Coronarography, CT-scan, anesthesia...

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To evaluate the effectiveness of an intervention combining a patient component and an organisational component
Tidsram: Month 6

Percentage of patients with a TAVI indication with a time to TAVI procedure of less than 2 months

Month 6

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time to care, in days
Tidsram: Month 6

The time to care is the number of days between the date of the initial consultation during which a TAVI is proposed and the date of the TAVI procedure

Month 6
Mortality rate
Tidsram: Months 3 and 6

The mortality rate will be measured between the initial consultation during which a TAVI is proposed and the TAVI procedure, and in the three months following the procedure

Months 3 and 6
Patients' health-related quality of life
Tidsram: Baseline, Months 3 and 6

Patients' health-related quality of life will be measured using the 5-level EQ-5D version (EQ-5D-5L).

Baseline, Months 3 and 6
Patient knowledge of the disease and the TAVI procedure
Tidsram: Baseline, Month 3

Patients' knowledge of the disease and the TAVI procedure will be measured by their score to an ad hoc questionnaire (0: minimum score - 26: maximum score).

Baseline, Month 3
Medication compliance
Tidsram: Month 6

Patient medication compliance will be measured using a questionnaire developed by Girerd et al, with a score going from 0 (lowest compliance) to 6 (maximum compliance).

Month 6
Patient satisfaction
Tidsram: Month 6

Patient satisfaction with the care they received and (for the group receiving the patient component) with the patient component of the intervention will be measured using a 0 to 10 Likert scale

Month 6
Number of visits to the patient section of the website
Tidsram: Month 6

The number of visits to the website will be assessed through Googleanalytics®

Month 6
Number of visits to the professional section of the website
Tidsram: Month 6

The number of visits to the website will be assessed through Googleanalytics®

Month 6
Acceptability of the intervention for participating centers
Tidsram: Month 6

The acceptability of the intervention will be assessed through an ad hoc questionnaire addressed to TAVI centers and peripheral hospitals performing the coronary angiography of the pre-TAVI assessment.

Month 6
Intervention components' dose and fidelity
Tidsram: Month 6

Number of different activities really performed for each component of the intervention / number of activities planned for each component according to the protocol.

Month 6
Reached populations
Tidsram: Month 6

Percentage of target individuals who benefit from activities of each component of the intervention

Month 6
Intervention components' adaptation
Tidsram: Month 6

Number of activities performed which have been modified to adapt them to the local context / total number of activities performed. A description of the adaptations performed will be provided.

Month 6
Incremental cost-effectiveness ratio
Tidsram: Month 6

The incremental cost-effectiveness ratio will be expressed in cost per quality-adjusted life-year (QALY) gained, derived from the EQ-5D-5L questionnaire

Month 6

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Helene Eltchaninoff, Pr, University Hospital, Rouen

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

26 oktober 2022

Primärt slutförande (Faktisk)

23 oktober 2025

Avslutad studie (Faktisk)

23 oktober 2025

Studieregistreringsdatum

Först inskickad

23 december 2021

Först inskickad som uppfyllde QC-kriterierna

11 februari 2022

Första postat (Faktisk)

14 februari 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 februari 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera